NOVN.SW Novartis AG SIX after hours CHF122.00 (-1.02%) 10 Mar 2026: Earnings focus

Novartis AG (NOVN.SW) traded at CHF122.00 in after hours on SIX on 10 Mar 2026, down -1.02% after a regular session that posted 4,062,349.00 shares. NOVN.SW stock shows short-term strength versus its 50-day average of CHF119.05 and a 200-day average of CHF105.09. Traders are parsing valuation and upcoming catalysts, led by a scheduled earnings announcement on 28 Apr 2026. We use price action, fundamentals and Meyka AI models to frame likely near-term moves for NOVN.SW stock.

NOVN.SW stock: Price action and volume

Novartis closed the regular session at CHF123.26 and moved to CHF122.00 after hours on 10 Mar 2026. The intraday range was CHF121.22 to CHF123.76. Volume was 4,062,349.00 versus an average of 3,334,508.00, making NOVN.SW stock one of the most active names on SIX today. The relative volume of 1.20 indicates outsized trading interest. Higher-than-normal volume suggests institutional rebalancing or positioning ahead of the April earnings date.

Price momentum shows a 3-month gain of 17.30% and a year-to-date rise of 15.48%, which helps explain why NOVN.SW stock is in the most active watchlists among Swiss healthcare names.

NOVN.SW stock: Fundamentals and valuation

Novartis posts an EPS of 5.57 and a trailing PE of 22.50 on a market cap of CHF239.09B. Key metrics show revenue per share 29.41, free cash flow per share 8.76, and dividend per share 4.49. Price-to-book stands at 6.69 and price-to-sales near 5.47, reflecting premium healthcare valuation. The payout ratio is 0.54, and dividend yield is about 2.79%.

Revenue and operating income growth remain positive, though net income fell last year. These fundamentals help explain why NOVN.SW stock trades at a premium to broad Swiss equities, even as analysts weigh Sandoz and Innovative Medicines segment trajectories.

NOVN.SW stock: Technicals and short-term signals

Short-term indicators are mixed. The RSI is 53.18, near neutral. MACD histogram is slightly negative at -0.92, while ADX at 26.50 signals a firm trend. Bollinger bands show a middle band at CHF126.58, with a lower band near CHF121.59, placing price close to the lower band. ATR is 2.55, suggesting daily moves of roughly CHF2.55.

Momentum oscillators such as Stochastic %K at 21.37 indicate near-oversold conditions. Traders watching NOVN.SW stock may look for a bounce toward the 50-day average CHF119.05 or a move above the middle Bollinger CHF126.58 to confirm upside continuation.

NOVN.SW stock: Sector context and comparative performance

Novartis sits in the Healthcare sector on SIX in Switzerland. The sector average PE is 30.01, so NOVN.SW stock at 22.50 is below sector average on PE but above peers on price-to-book. Over 3 months the Healthcare sector is down -0.19% while Novartis gained 17.30%, showing company-specific strength. Market capitalisation and global footprint keep Novartis in the top tier of Swiss healthcare names.

Sector trends — especially biotech approvals and generic competition — remain key. Investors comparing NOVN.SW stock to Roche and other drug manufacturers should weigh Novartis’ stronger free cash flow yield of 5.45% against pipeline and Sandoz margin pressures.

NOVN.SW stock: Meyka grade and analyst forecast

Meyka AI rates NOVN.SW with a score out of 100: 78.36 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score balances strong profitability metrics with higher price-to-book and debt signals.

Meyka AI’s forecast model projects a quarterly target of CHF137.85 and a yearly target of CHF117.11. Versus current price CHF122.00, the quarterly model implies an upside of 13.03%, while the yearly model implies a downside of -4.01%. Forecasts are model-based projections and not guarantees.

NOVN.SW stock: Risks and catalysts to watch

Primary catalysts include the earnings report on 28 Apr 2026, pipeline readouts, and regulatory news on biosimilars. Positive surprises could trigger a move toward the quarterly model target CHF137.85, while weaker Sandoz margins or regulatory setbacks could push price below CHF115.00.

Key risks for NOVN.SW stock are generic pressure in key markets, currency swings for Swiss-based revenues, and any guidance cut tied to margin or R&D timing. Monitoring insider activity and volume spikes ahead of earnings gives additional short-term signals.

Final Thoughts

NOVN.SW stock traded at CHF122.00 after hours on 10 Mar 2026, with 4,062,349.00 shares changing hands and a modest -1.02% move. Valuation metrics — EPS 5.57, PE 22.50, price-to-book 6.69 — show a premium but are supported by solid free cash flow and a 2.79% yield. Short-term technicals are mixed, with neutral RSI 53.18 and ADX 26.50 suggesting trend strength but limited momentum. Meyka AI’s forecast model projects a near-term quarterly target of CHF137.85 (implied upside 13.03%) and a year forecast CHF117.11 (implied downside -4.01%) compared with the current price CHF122.00. These model outputs highlight a scenario split: upside if earnings and pipeline catalysts surprise, downside if Sandoz pressure or guidance misses persist. Use the April earnings date as the next decisive catalyst. Meyka AI provides this as an AI-powered market analysis platform input; forecasts and grades are model-driven projections and are not guarantees or investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.